Caisse DE Depot ET Placement DU Quebec Has $147.28 Million Stock Holdings in United Therapeutics Corporation $UTHR

Key Points

• Caisse DE Depot ET Placement DU Quebec has increased its stake in United Therapeutics Corporation by 22.5%, owning approximately 1.06% of the company worth $147.3 million.
• United Therapeutics reported an EPS of $6.41 for the last quarter, missing the consensus estimate of $6.80 and generating revenue of $798.6 million, below expectations of $802.1 million.
• The company's stock has a consensus rating of "Moderate Buy" from analysts, with a consensus price target of $382.00.

Caisse DE Depot ET Placement DU Quebec raised its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 22.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 477,757 shares of the biotechnology company's stock after purchasing an additional 87,664 shares during the period. Caisse DE Depot ET Placement DU Quebec owned approximately 1.06% of United Therapeutics worth $147,278,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in UTHR. Dunhill Financial LLC increased its holdings in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares in the last quarter. SVB Wealth LLC bought a new stake in shares of United Therapeutics in the first quarter worth about $32,000. Sound Income Strategies LLC bought a new stake in shares of United Therapeutics in the first quarter worth about $49,000. State of Wyoming bought a new stake in shares of United Therapeutics in the fourth quarter worth about $62,000. Finally, Brooklyn Investment Group increased its holdings in shares of United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 98 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity

In other news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director directly owned 4,883 shares of the company's stock, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,681 shares of company stock worth $24,537,839. Insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

NASDAQ:UTHR traded up $1.89 during trading hours on Thursday, reaching $307.24. 749,916 shares of the company were exchanged, compared to its average volume of 790,149. The company has a market capitalization of $13.86 billion, a P/E ratio of 11.99, a P/E/G ratio of 4.63 and a beta of 0.57. The business has a 50 day moving average of $298.38 and a 200 day moving average of $306.47. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period last year, the firm earned $5.85 EPS. The firm's revenue for the quarter was up 11.7% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Bank of America lowered their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. HC Wainwright set a $400.00 price target on shares of United Therapeutics and gave the company a "buy" rating in a research note on Thursday, July 31st. Morgan Stanley dropped their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Finally, UBS Group raised their price objective on United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $382.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.